Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?
Where this comes from
- Record sourced from PubMed, PMID 12022380.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cancer patients and their families often ask their primary care physicians if a new treatment reported in the news can help them. Physicians familiar with the long and complicated process of oncologic clinical trials are in the best position to assess the potential for clinical benefit from a new antineoplastic therapy.